Business
Zhongchao Inc. Promotes Standardized Liver Cancer Diagnosis and Treatment with Medical Associations and Experts
SHANGHAI, Jan. 13, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a healthcare services company offering patient
About this update from Zhongchao Inc.
[{"type":"text","content":"SHANGHAI, Jan. 13, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) (\"Zhongchao\" or the \"Company\"), a healthcare services company offering patient management, online healthcare information, professional training and educational services, today announced that it co-sponsored the National Annual Conference for Standardized Liver Cancer Diagnosis and Treatment (the \"Annual Conference\") with China Association of Health Promotion and Education and Chinese Society of Liver Cancer.\nIn 2020, Zhongchao worked with medical associations and experts to jointly carry out a multi-year online education project on the diagnosis and treatment of primary liver cancer. This project aims to promote and implement the Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2019 Edition) (the \"Guidelines\") published by the National Health Commission of the People's Republic of China. Based on the professional interpretation and through its online platform, Zhongchao facilitated training and implementation of the Guidelines in over 200 cities for more than half a million medical professionals. The Annual Conference provided a timely platform for us to review last year's trainings on the standardized liver cancer diagnosis and treatment. Participants of the Annual Conference boasted seven fellows of Chinese Academy of Sciences, two renowned professors and five executive chairmen from the editorial board of the Guidelines. They led and joined discussions about clinical experience and benefits of the Guidelines, and ways to improve and update the Guidelines.\nJia Fan, Chinese Academy of Sciences Fellow, President of Zhongshan Hospital at Fudan University, and General Supervisor of the Guidelines, stated in the Annual Conference, \"prolonging patients' life is the most pressing issue in the field of liver cancer treatment in China. We draft and continuously update the Guidelines based on research developments and lead doctors' clinical practice. We collect practitioners' feedback on clinical application, such as the actual effects of standardized diagnosis and treatment of liver cancer patients, to ensure that the Guidelines are adjusted and updated to adapt to China's evolving environment and doctors and patients' real needs.\"\nWeiguang Yang, Chairman and Chief Executive Officer of Zhongchao, commented, \"Every update of the G...